Boston Scientific (BSX) weekly implied volatility at 51 into Q2
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Boston Scientific (BSX) PT Raised to $32 at Cowen
July 27, 2017 3:50 PM EDTCowen raised its price target on Boston Scientific (NYSE: BSX) to $32.00 (from $31.00) while maintaining a Outperform rating.
Management revised full year 2017 guidance and effectively kept the midpoint of the organic revenue guidance range intact at 5.8% while raising the EPS target by $0.01.
... MoreStifel Reiterates Buy on Boston Scientific (BSX) Following 2Q
July 27, 2017 1:41 PM EDTStifel reiterated a Buy rating and $32.00 price target on Boston Scientific (NYSE: BSX) following the company's 2Q. Revenue at $2.257 billion grew 6% reported and on organic basis, and 7% on an operational basis. BSX modestly raised the top-end of its previous 2017 organic sales growth... More
